Impact of policy changes and drug shortages on acamprosate and naltrexone use in Ontario, Canada

Original research
par
Konstantelos, Natalia et al

Date de publication

2023

Géographie

Canada

Langue de la ressource

English

Texte disponible en version intégrale

Non

Open Access / OK to Reproduce

Non

Évalué par des pairs

Yes

L’objectif

Acamprosate and naltrexone, evidence-based pharmacotherapies for alcohol use disorder (AUD), are publicly covered by the Ontario Drug Benefit (ODB) programs; however, their availability has changed over time, with expanded formulary access in July 2018, followed by an acamprosate shortage in February 2019 and ending in July 2020. We evaluated the impact of these events on the use of these medications in Ontario, Canada.

Constatations/points à retenir

Although coverage expansion increased access to medications that treat AUD, the shortage of acamprosate led to large reductions in its use, with no responsive increase in naltrexone prescribing.

La conception ou méthodologie de recherche

Time-series analysis (n=10,637)

Mots clés

Policy/Regulatory
About prescribers
Outcomes